Can intranasal drug use reduce HCV infection among injecting drug users?

被引:11
|
作者
Des Jarlais, Don C. [1 ]
Hagan, Holly [2 ]
Arasteh, Kamyar [1 ]
McKnight, Courtney [1 ]
Semaan, Salaam [3 ]
Perlman, David C. [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, New York, NY 10038 USA
[2] NYU, New York, NY 10003 USA
[3] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA
基金
美国国家卫生研究院;
关键词
Injecting; Non-injecting; Intranasal drug use; HCV; HEPATITIS-C VIRUS; RISK-FACTORS; TRANSITION; HEROIN; SEROCONVERSION; PREVALENCE; PREVENTION; OUTCOMES; ROUTE;
D O I
10.1016/j.drugalcdep.2011.06.020
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Preventing HCV infection among people who inject drugs is a difficult public health challenge. We examined the potential role of intranasal drug use in reducing HCV acquisition. Methods: Subjects were recruited from IDUs entering the Beth Israel drug detoxification program from 2005 to 2010. A structured interview was administered and serum samples were collected for HCV testing. Results: 726 active injecting drug users were recruited from 2005 to 2010. HCV prevalence was 71%, 90% reported recent heroin injection and 44% reported recent intranasal heroin use. In a multiple logistic regression analysis, being HCV seropositive was associated with more years injecting, Latino ethnicity, previous testing for HCV, and recent injection of speedball, and negatively associated with recent intranasal use of heroin (AOR = 0.52, 95% CI 0.33-0.82) and intranasal use of speedball (AOR = 0.41, 95% CI 0.31-0.80). The association between intranasal heroin use and lower HCV seroprevalance was observed among both new injectors and persons with long injecting histories (16+ years since first injection). Conclusion: Encouraging intranasal use as an alternative to injection among persons currently injecting drugs may be a viable strategy for reducing HCV transmission. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
下载
收藏
页码:201 / 206
页数:6
相关论文
共 50 条
  • [1] HIV and HCV infection among injecting drug users
    Hagan, H
    Jarlais, DCD
    MOUNT SINAI JOURNAL OF MEDICINE, 2000, 67 (5-6): : 423 - 428
  • [2] HCV Infection among Injecting Drug Users in Prishtina, Kosovo
    Jakupi, Xhevat
    Lunar, Maja M.
    Mlakar, Jana
    Matkovic, Ivana
    Tavakoli, Norma P.
    Ivanovska, Beti Zafirova
    Vince, Adriana
    Poljak, Mario
    HEPATITIS MONTHLY, 2018, 18 (10)
  • [3] Global overview of injecting drug use and HIV infection among injecting drug users
    Aceijas, C
    Stimson, GV
    Hickman, M
    Rhodes, T
    AIDS, 2004, 18 (17) : 2295 - 2303
  • [4] Global estimates of prevalence of HCV infection among injecting drug users
    Aceijas, Carmen
    Rhodes, Tim
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2007, 18 (05) : 352 - 358
  • [5] Managing HCV infection in injecting drug users: A community model
    Jack, Kate
    Varnam, Michael
    Thomson, Brian J.
    HEPATOLOGY, 2006, 44 (04) : 340A - 340A
  • [6] ACTIVELY INJECTING DRUG USERS CAN BE SUCCESSFULLY TREATED WITH ANTIVIRAL THERAPY FOR HCV, ARE UNLIKELY TO BE RE-INFECTED, AND SIGNIFICANTLY REDUCE THEIR ILLICIT DRUG USE
    Lewis, Heather
    Ibrahim, Nader
    Mirza, Maisum
    Hothi, Jasdip
    Wilkinson, Mandie
    Foster, Graham R.
    HEPATOLOGY, 2011, 54 : 846A - 847A
  • [7] ACTIVELY INJECTING DRUG USERS CAN BE SUCCESSFULLY TREATED WITH ANTIVIRAL THERAPY FOR HCV, ARE UNLIKELY TO BE RE-INFECTED, AND SIGNIFICANTLY REDUCE THEIR ILLICIT DRUG USE
    Lewis, H.
    Ibrahim, N.
    Mirza, M.
    Hothi, J.
    Wilkinson, M.
    Foster, G.
    GUT, 2011, 60 : A9 - A10
  • [8] High prevalence of HBV and HCV among injecting and non injecting drug users in Italy
    Camoni, L.
    Regine, V.
    Salfa, M. C.
    Raimondo, M.
    Bruning, A. H. L.
    Nicoletti, G.
    Canuzzi, P.
    Magliocchetti, N.
    Rezza, G.
    Suligoi, G.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2010, 20 : 207 - 207
  • [9] BENZODIAZEPINE USE AMONG INJECTING DRUG-USERS
    SEIVEWRIGHT, N
    ADDICTION, 1994, 89 (12) : 1701 - 1703
  • [10] Can HCV be prevented among injection drug users?
    Newmeyer, J
    JOURNAL OF PSYCHOACTIVE DRUGS, 2002, 34 (04) : 421 - 425